Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q14833
UPID:
GRM4_HUMAN
Alternative names:
-
Alternative UPACC:
Q14833; B3KVL9; B7Z1T9; B7Z1U6; F5GXM5; Q5SZ84; Q6ZMQ2
Background:
The Metabotropic Glutamate Receptor 4 (mGluR4) plays a pivotal role in neurotransmission, acting as a G-protein coupled receptor for glutamate. This receptor's activation leads to a conformational change, initiating signaling through G proteins and modulating the activity of downstream effectors, notably inhibiting adenylate cyclase.
Therapeutic significance:
Understanding the role of Metabotropic Glutamate Receptor 4 could open doors to potential therapeutic strategies. Its involvement in neurotransmission suggests its potential as a target in neurological disorders.